Overview of Prostasil

Property	Description
Active ingredient	Dutasteride
Form	Soft gelatin capsule (Oral)
Pharmacological class	5alpha-Reductase Inhibitor
Common use	Management of prostatic enlargement
Origin	Synthetic 4-azasteroid compound

What Type of Medicine is Prostasil?

Prostasil is a prescription oral medication containing the active ingredient Dutasteride, and it is formally classified as a 5alpha-Reductase Inhibitor. The drug is a synthetic 4-azasteroid compound and is supplied for oral administration as a soft gelatin capsule.

Dutasteride belongs to the pharmacological group of androgen inhibitors due to its specific chemical mechanism. The capsule formulation is necessitated by the compound's very low aqueous solubility and utilizes an oily substrate to ensure the active compound is delivered effectively upon ingestion. Prostasil, as a distinct brand, is positioned for the long-term management of chronic prostatic growth in adult males to alleviate symptoms associated with an enlarged prostate.

How Does Prostasil Differ from Other Therapies?

Prostasil is distinguished as a dual 5alpha-reductase inhibitor because its active ingredient, Dutasteride, is an irreversible inhibitor that potently targets both the Type 1 and Type 2 isoforms of the enzyme. These two isoforms of the 5alpha-reductase enzyme are responsible for converting Testosterone into the more potent growth-stimulating hormone, 5alpha-Dihydrotestosterone (DHT), within the body.

The dual inhibition achieved by Prostasil results in a profound and comprehensive suppression of both serum and prostatic DHT levels. This action provides superior or equivalent efficacy in achieving hormonal suppression compared to single-isoform inhibitors. This hormonal blockade represents a structural intervention, fundamentally differing from therapies that focus purely on relaxing the smooth muscles of the prostate to relieve physical obstruction.

What is the General Purpose of Prostasil?

The general purpose of Prostasil is to manage conditions associated with prostatic growth by reducing the size of the enlarged tissue. By significantly limiting the production and action of DHT, the drug addresses the primary hormonal stimulus for cell proliferation within the prostate. This approach is intended to modify the disease progression by reducing the physical burden of the enlarged tissue.

This physiological effect is foundational to the drug's therapeutic goal, as the resultant shrinkage of the prostate gland provides a basis for sustained structural relief. This structural reduction of prostate volume is a key therapeutic outcome of Dutasteride. The function is to modify the underlying size of the enlarged tissue, providing a benefit for the long-term management of chronic prostatic enlargement.

Regulatory References

What side effects are possible with Prostasil?

Possible Side Effects and Safety Information

The safety profile for Prostasil (Dutasteride) is primarily defined by adverse reactions classified by frequency as documented in official regulatory labeling. These effects are grouped by the affected body system, providing a structural overview of potential risks.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions affect the Reproductive System and Breast Disorders:

Common (may affect up to 1 in 10 people): Impotence, decreased libido, ejaculation disorders, and breast disorders (including gynecomastia, tenderness, and enlargement).
Uncommon (may affect up to 1 in 100 people): Cardiac failure (a composite term) and skin reactions like alopecia or hirsutism.
Rare: Severe hypersensitivity reactions, including angioedema.
Frequency Not Known: Depressed mood, depression, testicular pain, and testicular swelling have been reported in the post-marketing setting.

Time-Related and Population Safety Constraints

The label notes that sexual adverse events are typically more frequent during the first year of treatment but tend to decrease with continued use. However, the persistence of sexual dysfunction after discontinuing the medication is a documented safety concern.

Serious Adverse Reactions officially noted include angioedema and the documentation of an increased incidence of high-grade prostate cancer (Gleason 8–10) observed in clinical trials, as well as post-marketing reports of male breast cancer.

Safety Restrictions define specific constraints for high-risk populations. The medication is contraindicated in women (especially pregnant or potentially pregnant women) due to the risk of abnormal external genital development in a male fetus, in children, and in individuals with severe hepatic impairment. Furthermore, patients must not donate blood until at least six months after the last dose, and measures must be taken to prevent exposure of a pregnant partner to the patient's semen.

Overdose and Emergency Response

The official regulatory profile for Prostasil (Dutasteride) does not specify a distinct set of acute symptoms or clinical manifestations of overdose. Clinical studies involving exposure to doses significantly higher than the recommended amount did not result in the documentation of new or specific safety concerns.

Despite the absence of specific acute manifestations, regulatory guidance mandates that any suspected overdose requires immediate emergency medical attention or contact with a Poison Control Center. This is required to ensure necessary clinical monitoring and supportive care.

The primary management approach is strictly focused on providing symptomatic and supportive treatment, as there is no specific antidote known or available for the active ingredient. Due to the pharmacological properties of the drug—specifically its extensive protein binding and very large volume of distribution—standard intervention procedures such as dialysis are not expected to be useful for removing the compound from the systemic circulation.

Close medical observation is required in overdose situations due to the active substance's prolonged elimination half-life, which can extend over several weeks. A general caution regarding potential prolonged systemic exposure is noted for patients with hepatic impairment, given the drug’s metabolic elimination pathway.

Therapeutic Uses of Prostasil

What Prostasil Treats: Main Uses and Benefits

Prostasil is commonly used in the management of symptomatic Benign Prostatic Hyperplasia (BPH) in men with an enlarged prostate, supporting improved symptom management and assisting with the management of associated risks. The medication is relevant for long-term therapeutic assistance, primarily addressing chronic prostatic growth, Lower Urinary Tract Symptoms (LUTS), and related complication risks.

Structural and Symptomatic Support

Prostasil is relevant for easing symptomatic discomfort by managing the progression of the underlying condition in men with moderate-to-severe symptoms. It is used to help address symptom clusters of LUTS, which include voiding difficulties (like weak stream and hesitancy) and storage symptoms (such as urgency, frequency, and nocturia). This assists with maintaining functional stability and supports improved day-to-day comfort during symptomatic periods.

Mitigation of Serious BPH-Related Risks

Prostasil is commonly used to help manage the long-term risk of developing serious BPH-related complications, specifically Acute Urinary Retention (AUR) and the potential subsequent need for BPH-related surgical intervention. It is applied in clinical settings where the goal is the structural management of the underlying condition, providing supportive assistance relevant for the chronic management of prostate tissue growth.

Quick Fact: Symptom Management
Prostasil is commonly used to help manage both the voiding difficulties and the storage symptoms of LUTS, supporting the patient during episodes of heightened discomfort related to prostate enlargement.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Prostasil — Official Regulatory Information

The eligibility profile for Prostasil (Dutasteride) is defined strictly by regulatory authorities, limiting its use to Adult Males for the management of symptomatic benign prostatic hyperplasia.

Eligibility Scope

Population Group	Eligibility Status (Regulatory Wording)
Adult Males	Approved for use in the adult male population. No dose adjustment is generally necessary for older adults (geriatric use).
Women (General)	Contraindicated for use by women [Source 1.4, 2.4].
Pregnancy	Contraindicated in females who are pregnant or may become pregnant due to the risk of fetal harm [Source 1.4].
Pediatric Patients	Contraindicated in children and adolescents, as safety and efficacy have not been established [Source 1.4, 2.4].
Severe Hepatic Impairment	Contraindicated in patients with severe liver disease [Source 2.4, 2.5].
Mild to Moderate Hepatic Impairment	Caution should be used in administration [Source 1.1, 2.5].
Hypersensitivity	Contraindicated in patients with known allergy to Dutasteride, other 5alpha-reductase inhibitors, or any excipients [Source 1.4, 2.4].

Eligibility-Related Restrictions

Blood Donation: Men taking Prostasil should not donate blood until at least 6 months have passed since the last dose, a precaution to prevent the drug from reaching a pregnant female recipient [Source 1.4].
Handling Capsules: Women who are pregnant or may become pregnant must not handle the capsules, as the active ingredient can be absorbed through the skin [Source 1.4, 1.6].
Renal Impairment: No dose adjustment is anticipated for patients with renal impairment [Source 1.5, 3.4].

Connection to the Overall Eligibility Profile

Official regulatory documents establish a profile that restricts use almost entirely to Adult Males. This results in an absolute contraindication for all women, particularly those who are pregnant, and for the pediatric population. Use is also formally contraindicated by regulatory authorities in patients with severe hepatic impairment or a history of significant hypersensitivity to the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Prostasil (dutasteride and tamsulosin) carries risks of interaction primarily related to the tamsulosin component's metabolism and its effects as an alpha-adrenergic antagonist. Understanding these interactions is vital to prevent serious adverse events such as significant hypotension or increased drug exposure.

Pharmacokinetic Interactions (Metabolism)

The tamsulosin component is primarily metabolized by the liver enzymes Cytochrome P450 (CYP) 3A4 and CYP2D6. Combining Prostasil with medicines that strongly inhibit these enzymes can significantly increase tamsulosin levels in the body, which may increase the risk of side effects.

Classification	Interacting Medicines/Classes	Risk and Action
Contraindicated	Strong CYP3A4 inhibitors (e.g., ketoconazole)	Significant increase in tamsulosin exposure. Do not co-administer.
Use with Caution	Moderate CYP3A4 inhibitors (e.g., erythromycin); Strong/Moderate CYP2D6 inhibitors (e.g., paroxetine)	Potential for increased tamsulosin exposure. Caution and monitoring are advised.

Pharmacodynamic Interactions (Hypotension)

Both tamsulosin and other medicines that cause vasodilation can have an additive effect on lowering blood pressure, which may lead to symptomatic hypotension (dizziness, fainting).

Interacting Medicines/Classes	Risk and Action
Other Alpha Adrenergic Antagonists (e.g., prazosin, alfuzosin)	Increased risk of symptomatic hypotension. Do not co-administer.
Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil)	Increased risk of symptomatic hypotension. Use with caution.

Additional Notes: Caution is also advised when co-administering with cimetidine and warfarin.

Mechanism of Action

Mechanism of Action: How Prostasil Works

Prostasil (Dutasteride) exerts its action by intervening at the core of the androgen metabolic pathway, leading to structural changes at the tissue level. The mechanism operates across three key domains:

Dual Inhibition of the 5alpha-Reductase Enzyme

The drug's primary mechanistic focus is the irreversible inhibition of both the Type 1 and Type 2 isoforms of the 5alpha-Reductase enzyme. This molecular blockade prevents the conversion of Testosterone into the highly active androgen, Dihydrotestosterone (DHT), thereby suppressing the principal hormonal growth stimulus within the tissue.

Structural Regression Via Cell Apoptosis

The suppression of DHT levels removes a major trophic signal supporting prostate cell survival and proliferation. This shift in cellular balance favors apoptosis (programmed cell death), leading to a sustained, net loss of cells. This mechanistic cascade results in the physical reduction in the overall volume and mass of the prostate gland tissue.

Time-Dependent Structural Change

The consequence of DHT suppression is the gradual structural reversal of the prostate tissue. Since this effect relies on the accumulation of cell death and the physical shrinking of the gland, the maximal structural change occurs gradually over many months. The mechanism targets the static component of the tissue volume but does not provide acute modulation of smooth muscle tone.

Dosage and Administration Information

How to Use Prostasil: Administration Guidelines

This section describes the standard administration of Prostasil (Dutasteride), focusing strictly on procedural use and dosing parameters.

Administration Scope

Category	Standard Instruction
Route of administration	Oral
Dosing schedule	One 0.5 mg soft gelatin capsule
Timing in relation to meals	May be taken with or without food.
Preparation requirements	The capsule must be swallowed whole and must not be chewed, opened, or crushed, as the contents may cause oropharyngeal irritation.
Age-group administration rules	Elderly (Geriatric) and Renal Impairment: No dose adjustment is generally required. Hepatic Impairment: Caution should be exercised; however, no specific dose recommendation exists due to limited data.
Missed-dose rules	If a dose is missed, the regimen should be resumed with the next scheduled daily dose. Patients must not take a double dose to compensate for a forgotten capsule.
Special procedural conditions	The capsule should be administered at approximately the same time each day to maintain consistent systemic exposure for chronic management.

Resulting Procedural Structure

Standard administration for Prostasil involves a once-daily, oral use of the intact 0.5 mg capsule. The primary constraint on preparation is that the capsule must be ingested whole, regardless of whether it is taken with food. This regimen is established for long-term, chronic management, often requiring continuous daily use for up to six months to observe the full structural effect of the medicine. Adherence to the fixed daily schedule and proper administration method is part of the standard administration method.

Recent Clinical Evidence

Clinical Evaluation for Benign Prostatic Hyperplasia (BPH)

This section summarizes the main body of research, which includes Randomized Controlled Trials (RCTs) and systematic reviews, that was used to evaluate Prostasil in clinical settings. This research was applied in studies examining patient-reported experiences in adult men experiencing symptoms associated with chronic prostate enlargement.

Studies on Symptom and Functional Measures

Research explored the study drug’s application in individuals experiencing outcomes related to physical discomfort and daily functioning associated with BPH. The main outcomes that were monitored included changes in urinary symptom severity, often measured using tools like the International Prostate Symptom Score (IPSS), and patient-reported outcomes describing perceived discomfort (Quality of Life metrics). Studies also monitored outcomes reflecting daily functioning, such as changes in the Maximum Urinary Flow Rate ( Q max). Findings describe patterns observed in the studies related to symptom evolution over the observation periods, and research explored the monitoring of structural change, with studies monitoring changes in the physical volume of the prostate gland over time.

Research on Long-Term Risk of Progression

The evidence includes studies that monitored outcomes describing episodic or acute changes, specifically examining the risk of BPH-related events such as Acute Urinary Retention (AUR) and the need for surgery. Research explored the incidence of AUR and surgical intervention related to BPH in populations studied with the medicine. The evidence contributes to understanding symptom patterns and the progression of conditions characterized by fluctuating or episodic manifestations.

Duration of Study and Extended Follow-Up

Prostasil was evaluated in studies observing responses over defined time intervals. The initial symptom-related findings often come from research exploring short-term symptom changes over periods such as 6 to 12 months. To understand long-term findings related to prostate volume and event risk, research also examined outcomes over extended observation periods, with key clinical trials providing follow-up data for up to 4 years (48 months). This extended data describes patterns in how patients reported their experience over years, but research exploring outcomes for maintenance and progression risk beyond the four-year mark are not as well characterized.

Key Limitations and Research Gaps

The scientific literature identifies areas where data are still emerging or where the evidence is limited. The evidence includes heterogeneity in reported outcome measurements in trials that used an active comparator. The existing heterogeneity in comparative findings indicates that evidence quality varies across studies regarding specific symptom and QoL measurements. Additionally, while the long-term observation period extends up to four years, long-term effects are not fully established beyond that time frame. The study results reflect the specific conditions under which they were conducted and apply primarily to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Prostasil (FAQ)

Q: Will I feel the effects of Prostasil immediately or does it take time?

A: Studies and official information indicate that the full therapeutic response, including the maximum structural change to the prostate tissue, is gradual. Because the medicine works by slowly reducing the size of the enlarged tissue, the full effect may be observed only after continuous use for up to six months or more.

Q: What are the most commonly reported side effects of Prostasil?

A: Regulatory documents state that the most commonly reported adverse reactions affect the reproductive system. These effects typically include impotence, decreased libido, ejaculation disorders, and breast disorders such as enlargement and tenderness. It is noted that these effects are often more frequent during the first year of treatment.

Q: Can Prostasil cause any issues with sexual function or libido?

A: Yes, official product information lists issues affecting the reproductive system as common adverse reactions. These include the possibility of impotence (difficulty getting or keeping an erection), decreased sexual desire (libido), and ejaculation disorders. The persistence of sexual dysfunction after stopping the medication is a documented safety concern.

Q: What is the list of medications or supplements that Prostasil may interact with?

A: Regulatory documents describe interactions primarily with medications that affect the liver's metabolism enzymes, specifically strong or moderate inhibitors of CYP3A4 and CYP2D6. The drug may also interact with other alpha-adrenergic antagonists and requires caution when used with PDE-5 inhibitors (like tadalafil or sildenafil).

Q: What happens if I suddenly stop taking Prostasil?

A: The active ingredient in Prostasil has a long elimination half-life, meaning it remains in the body for up to four to six months after the last dose. Official safety information notes that sexual dysfunction is a concern that may persist even after the medication has been discontinued.

Q: Is dizziness a commonly reported side effect when starting Prostasil?

A: When Prostasil is formulated to include an alpha-blocker (tamsulosin), dizziness is listed in the official documents as one of the most common adverse reactions reported by subjects starting the combination therapy. This effect may be related to changes in blood pressure, as the medication is a vasodilator.

Q: What does the research evidence say about the effectiveness of Prostasil for BPH symptoms?

A: Studies indicate that the drug is indicated to improve urinary symptoms and research explored its ability to manage discomfort related to BPH. Furthermore, research explored its ability to reduce the risk of BPH-related complications such as acute urinary retention (AUR) and the need for surgery.

Q: Are there any studies comparing the long-term effectiveness of Prostasil to other BPH treatments?

A: Regulatory documents refer to clinical trials that explored the use of the drug in combination with an alpha-adrenergic antagonist (like tamsulosin) compared to each drug alone. Some of these studies have provided follow-up data for observation periods extending up to four years.

Q: Does the drug have a generic version available?

A: The active ingredient in Prostasil is dutasteride. According to official approval information, dutasteride is available in generic formulations from various manufacturers, in addition to its branded and combination product forms.

Q: Is a decrease in ejaculate volume possible while taking Prostasil?

A: Yes, regulatory documents list ejaculation disorders as a common side effect of the medicine. Clinical studies have specifically documented a mean percent reduction in semen volume when compared to the measurements taken before starting treatment.

Q: Can I take Prostasil if I am already taking medicine for high blood pressure (hypertension)?

A: The official product information states that Prostasil can cause orthostatic hypotension (a drop in blood pressure when standing up). Caution is advised when the drug is taken alongside other medications that can also lower blood pressure.

Q: Is there a known interaction between Prostasil and alcohol?

A: When the medication contains an alpha-blocker component (tamsulosin), regulatory documentation indicates that the use of alcohol can increase the risk of lowering blood pressure. This effect may lead to symptoms like dizziness.

Q: Does taking Prostasil affect the results of a PSA (Prostate-Specific Antigen) test?

A: Yes, the official label includes a warning that the drug reduces total serum PSA concentration by approximately 50% after about six months of continuous treatment. For accurate interpretation, the PSA value is typically adjusted by a healthcare provider while a patient is on this medication.

Q: What is the difference between Prostasil and other common prostate drugs like tamsulosin or finasteride?

A: Prostasil's active ingredient, dutasteride, is a dual 5alpha-reductase inhibitor that works by reducing the physical size and volume of the prostate tissue. This mechanism differs from that of tamsulosin (an alpha-blocker), which acts by relaxing smooth muscle. It is similar to finasteride but differs by inhibiting both Type 1 and Type 2 5alpha-reductase enzymes.

Q: Does Prostasil only treat symptoms, or does it slow down prostate growth?

A: Regulatory documents indicate that the drug is approved to both improve symptoms and manage the disease progression. It works by causing a reduction in the size and volume of the prostate, which is key to reducing the risk of BPH-related surgery or acute urinary retention.

Q: What is the risk of breast enlargement (gynecomastia) mentioned with drugs similar to Prostasil?

A: Official adverse reaction data for Prostasil itself lists breast disorders as a common side effect. These disorders include breast enlargement (gynecomastia) and tenderness.

Q: Can Prostasil be taken at the same time as a PDE5 inhibitor like Cialis (tadalafil)?

A: Official drug information advises caution when the drug (in combination with tamsulosin) is taken alongside PDE-5 inhibitors. This is because both classes of drugs are vasodilators and their combined effect can increase the risk of symptomatic hypotension (low blood pressure).

Q: Does long-term use of Prostasil carry any specific risks or side effects?

A: Yes, regulatory warnings note a concern regarding the persistence of sexual dysfunction after the medication is discontinued. Additionally, an increased risk of high-grade prostate cancer was observed in clinical trials, which is a key long-term safety theme.

Q: Can Prostasil be taken along with other medications for the same condition?

A: The drug is available as a combination therapy with tamsulosin, indicating it can be used with other agents. However, official information states that it should not be coadministered with other alpha-adrenergic antagonists due to the increased risk of low blood pressure.

Q: Is there a specific age group Prostasil is recommended for?

A: Regulatory documents approve the drug for use only in Adult Males for the management of symptomatic BPH. No specific dose adjustment is generally required for older adults.

Q: Can Prostasil cause dry mouth or changes in taste?

A: In the post-marketing setting for the combination product, regulatory documents include reports of dry mouth as an adverse reaction. Other changes, such as in taste, are not consistently highlighted in the official product information.

Q: What are the official clinical trial themes related to the safety of Prostasil?

A: Safety themes highlighted in regulatory documents focus on: the persistence of sexual dysfunction, the observed risk of high-grade prostate cancer in trials, and the mandatory warning regarding the risk of fetal harm from exposure.

How should Prostasil be stored and disposed of?

How to Store and Dispose of Prostasil?

Prostasil (Dutasteride) must be stored and handled according to regulatory labeling to maintain its stability and integrity.

Storage Conditions

The medicine is required to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which must be tightly closed to ensure protection from light and moisture. Do not refrigerate or freeze Prostasil. Store the medicine out of the sight and reach of children.

Special Handling and Disposal

There is a mandatory handling instruction: women who are or may be pregnant must avoid contact with leaking soft gelatin capsules. For disposal, unused or expired Prostasil must be discarded according to local regulatory requirements, preferably utilizing an official drug take-back program. The medicine must not be disposed of in wastewater.

Prostasil